Last updated on April 20, 2014 at 21:20 EDT

Annual Shareholders’ Meeting of Cytos Biotechnology Ltd: Shareholders Approve All Resolutions

June 28, 2013

ZURICH, Switzerland, June 28, 2013 /PRNewswire/ –

Cytos Biotechnology Ltd (SIX:CYTN) today announced that its shareholders have approved
all resolutions at the Annual Shareholders’ Meeting 2013.

The Annual Shareholders’ Meeting of Cytos Biotechnology Ltd took place at the
company’s headquarters in Schlieren (Zurich), Switzerland. It was attended by 38
shareholders. 12,584,907 shares or 56.15% of a total of 22,411,431 shares were

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company focused on the development of targeted
immuno-therapies. The Company’s lead product candidate CYT003 is a first-in-class immune
modulator in Phase 2 clinical development as a potential new treatment for allergic

CYT003 acts via a novel, allergen-independent mechanism of action to selectively
suppress the body’s immune response to allergens, a predominant risk factor for asthma. In
a successfully completed Phase 2a study, CYT003 was shown to maintain asthma control and
lung function in patients with persistent allergic asthma, even as standard inhaled
corticosteroid treatment was withdrawn. CYT003 has been shown to be safe in over 450
patients to date.

Cytos was founded in 1995 as a spinoff from the Swiss Federal Institute of Technology
(ETH) in Zurich. It is located in Schlieren (Zurich), Switzerland. The Company is listed
according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.


This foregoing press release may contain forward-looking statements that include words
or phrases such as “are intended for”, “are designed to”, or other similar expressions.
These forward-looking statements are subject to a variety of significant uncertainties,
including scientific, business, economic and financial factors, and therefore actual
results may differ significantly from those presented. There can be no assurance that any
further therapeutic entities will enter clinical trials, that clinical trial results will
be predictive for future results, that therapeutic entities will be the subject of filings
for regulatory approval, that any drug candidates will receive marketing approval from the
U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will
be marketed successfully. Against the background of these uncertainties readers should not
rely on forward-looking statements. The Company assumes no responsibility to update
forward-looking statements or adapt them to future events or developments.

SOURCE Cytos Biotechnology Ltd

Source: PR Newswire